Seer Inc. receives Investment Bank Analyst Rating Update
Seer, Inc. (SEER) reported Q2 EPS of ($0.37), $0.02 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $3.6 million versus the consensus estimate of...
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
|Average||15.00 (+78.57% Upside)|
|No. of Analysts||2|